Comparative Pharmacology
Head-to-head clinical analysis: HYDREA versus LYSODREN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDREA versus LYSODREN.
HYDREA vs LYSODREN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyurea inhibits ribonucleotide reductase, thereby reducing the conversion of ribonucleotides to deoxyribonucleotides, which impairs DNA synthesis and leads to cell cycle arrest in S phase. It also induces fetal hemoglobin (HbF) production by increasing nitric oxide and soluble guanylyl cyclase activity.
Adrenocorticolytic agent; causes adrenal cortical necrosis and suppresses adrenal steroidogenesis, especially glucocorticoids and mineralocorticoids.
20-30 mg/kg orally once daily; typical adult dose 500 mg to 1.5 g daily. Maximum dose 2 g per day.
Oral, initial dose 2-6 g/day divided in 3-4 doses, increase gradually to 8-10 g/day. Maximum dose 18 g/day.
None Documented
None Documented
The terminal elimination half-life is approximately 3-4 hours in patients with normal renal function. In patients with creatinine clearance <60 mL/min, half-life may be prolonged up to 8-12 hours, necessitating dose adjustment.
18-159 days; clinical context: during chronic therapy, steady-state may not be reached for 3-6 months.
Renal excretion is the primary route of elimination, with 50-80% of an administered dose recovered as unchanged drug in urine within 24 hours. Biliary/fecal excretion accounts for less than 10%.
Primarily renal excretion of metabolites; about 10% as unchanged drug. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Antineoplastic
Antineoplastic